Search Results

You are looking at 101 - 110 of 1,114 items for :

  • "breast cancer" x
  • Refine by Access: All x
Clear All
Full access

Cesar A. Santa-Maria and Rita Nanda

reviews the experience with immune checkpoint blockade in breast cancer and future directions in therapeutic and biomarker strategies. Single-Agent Immune Checkpoint Experience Although there are many molecular subtypes of breast cancer, clinically

Full access

Amy A. Kirkham, Kelcey A. Bland, Holly Wollmann, Alis Bonsignore, Don C. McKenzie, Cheri Van Patten, Karen A. Gelmon, and Kristin Campbell

Background A critical aspect of breast cancer survivorship care includes addressing the negative sequelae of breast cancer therapy on health-related fitness and quality of life (QoL). The NCCN Clinical Practice Guidelines in Oncology (NCCN

Full access

Donna Trauth and Lori J. Goldstein

The authors have no financial interests, arrangement, or affiliations with the manufacturers of any products discussed in the article or with their competitors. References 1 Early Breast Cancer Trialists' Collaborative Group

Full access

Data adapted from Bergstrom et al. 1 Data based on reporting from 750 community oncology practices in the United States to McKesson Specialty Care Solutions. Adjuvant chemotherapy for breast cancer has evolved over several decades

Full access

Oxana Palesh, Arianna Aldridge-Gerry, Ayhan Ulusakarya, Elisabet Ortiz-Tudela, Lucile Capuron, and Pasquale F. Innominato

Women diagnosed with breast cancer experience a high prevalence of sleep disruption during treatment and survivorship. Sleep disruption encompasses a wide range of sleep disorders (eg, insomnia, restless legs syndrome, sleep apnea) in patients

Full access

Therese Bevers, Kirsten Bibbins-Domingo, Kevin C. Oeffinger, and Mary Lou Smith

At a panel discussion on controversies in breast cancer screening held recently at the NCCN 21st Annual Conference, representatives of the U.S. Preventive Services Task Force (USPSTF), American Cancer Society (ACS), and NCCN discussed the

Full access

C. Anthony Blau, Arturo B. Ramirez, Sibel Blau, Colin C. Pritchard, Michael O. Dorschner, Stephen C. Schmechel, Timothy J. Martins, Elisabeth M. Mahen, Kimberly A. Burton, Vitalina M. Komashko, Amie J. Radenbaugh, Katy Dougherty, Anju Thomas, Christopher P. Miller, James Annis, Jonathan R. Fromm, Chaozhong Song, Elizabeth Chang, Kellie Howard, Sharon Austin, Rodney A. Schmidt, Michael L. Linenberger, Pamela S. Becker, Francis M. Senecal, Brigham H. Mecham, Su-In Lee, Anup Madan, Roy Ronen, Janusz Dutkowski, Shelly Heimfeld, Brent L. Wood, Jackie L. Stilwell, Eric P. Kaldjian, David Haussler, and Jingchun Zhu

trials (ITOMIC-001) enrolls patients with metastatic triple-negative breast cancer (TNBC) ( ClinicalTrials.gov identifier: NCT01957514). Results from the first patient reported from this trial exemplify the approach. Methods Study Design

Full access

Colby J. Hyland, Flora Varghese, Christina Yau, Heather Beckwith, Katia Khoury, William Varnado, Gillian L. Hirst, Robert R. Flavell, A. Jo Chien, Douglas Yee, Claudine J. Isaacs, Andres Forero-Torres, Laura J. Esserman, and Michelle E. Melisko

Background Breast cancer accounts for 30% of new cancer diagnoses in women, with approximately 276,480 new invasive breast cancers expected in the United States in 2020. 1 The likelihood of metastatic disease at presentation is stage

Full access

Erica L. Mayer, Nancy U. Lin, and Harold J. Burstein

. Brown LF Berse B Jackman RW . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer . Hum Pathol 1995 ; 26 : 86 – 91 . 5. Guidi AJ Fischer L Harris JR Schnitt SJ . Microvessel

Full access

Tarek Safi, Pascale Salameh, Lea Aoude, Mirna Waked, FCCP, and Bassim Kobrossy

Background: Differences between left and right breast cancer have been investigated in the past in terms of incidence; it is higher on the left side than on the right. This difference has ranged from 2% to 5%. However, there are no publications